000			02027 a2200577 4500
005			20250514073504.0
264		0	_c20030904
008			200309s 0 0 eng d
022			_a0041-1337
024	7		_a10.1097/01.TP.0000071362.99021.D9 _2doi
040			_aNLM _beng _cNLM
100	1		_aKirk, Allan D
245	0	0	_aResults from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). _h[electronic resource]
260			_bTransplantation _cJul 2003
300			_a120-9 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAlemtuzumab
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Neoplasm _xtherapeutic use
650	0	4	_aBlack People
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aGraft Rejection _xepidemiology
650	0	4	_aGraft Survival _xdrug effects
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aKidney Transplantation _ximmunology
650	0	4	_aLymph Nodes _ximmunology
650	0	4	_aLymphocyte Depletion
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aT-Lymphocytes _ximmunology
650	0	4	_aTime Factors
650	0	4	_aTransplantation, Homologous
650	0	4	_aUnited States
650	0	4	_aWhite People
650	0	4	_aBlack or African American
700	1		_aHale, Douglas A
700	1		_aMannon, Roslyn B
700	1		_aKleiner, David E
700	1		_aHoffmann, Steven C
700	1		_aKampen, Robert L
700	1		_aCendales, Linda K
700	1		_aTadaki, Douglas K
700	1		_aHarlan, David M
700	1		_aSwanson, S John
773	0		_tTransplantation _gvol. 76 _gno. 1 _gp. 120-9
856	4	0	_uhttps://doi.org/10.1097/01.TP.0000071362.99021.D9 _zAvailable from publisher's website
999			_c12643660 _d12643660